Clinical Trials
29
Trial Phases
4 Phases
Drug Approvals
31
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
News
Iovance Biotherapeutics Names Corleen Roche as CFO During Commercial Launch of First FDA-Approved TIL Therapy
Iovance Biotherapeutics appointed Corleen Roche as Chief Financial Officer effective August 6, 2025, during the commercial launch of its groundbreaking TIL therapy.
Solu Therapeutics Appoints Enda Moran as COO to Scale CyTAC Platform Operations
Solu Therapeutics has appointed Enda Moran, PhD, MBA as Chief Operating Officer to lead operational functions as the company advances its Phase 1 clinical trial of STX-0712.
Vima Therapeutics Emerges with $60M to Develop First Oral Therapy for Dystonia
Vima Therapeutics launched with $60 million Series A funding led by Atlas Venture to advance VIM0423, a potential first-in-class oral therapy for dystonia targeting muscarinic cholinergic receptors.
SK Bioscience Wins Appeal Against Pfizer in Pneumococcal Vaccine Patent Dispute
SK Bioscience has successfully won an appeal against Pfizer's subsidiary Wyeth LLC in a patent dispute over pneumococcal vaccine components exported to Russia for research purposes.
WuXi PharmaTech Strengthens Board with Strategic Appointments of Industry Veterans
• WuXi PharmaTech has appointed several key executives to its Board of Directors, including Ying Han, Stewart Hen, and co-founder Ning Zhao, bringing valuable financial and pharmaceutical expertise to the company. • The strategic board appointments aim to enhance WuXi's business operations and financial systems as the company continues to expand its pharmaceutical R&D outsourcing services in China and the United States. • Co-founder Tao Lin has stepped down from his position on the board and as Vice President of Internal Operations, marking a significant leadership transition for the growing pharmaceutical services organization.